Welcome to our dedicated page for OneMedNet news (Ticker: ONMD), a resource for investors and traders seeking the latest updates and insights on OneMedNet stock.
OneMedNet Corp provides healthcare data and software solutions focused on regulatory-grade, AI-ready real-world data for life sciences, medical device, research, and AI customers. Company news commonly centers on the OneMedNet iRWD™ platform, its Palantir Foundry-powered search and data access capabilities, and the commercialization of subscription-based real-world data products.
Recurring developments include platform launches, bookings and revenue updates, data licensing agreements, and collaborations that expand disease-specific and multimodal datasets. Recent company updates have discussed oncology, autoimmune, neurotechnology, medical imaging, electronic health records, longitudinal patient data, cohort discovery, and real-world evidence generation.
OneMedNet (Nasdaq: ONMD) announced its OneMedNet iRWD™ Platform is live and fully operational on Palantir Foundry as of April 22, 2026.
The platform delivers searchable access to billions of records across 80 million patient journeys (a ~70% network increase), 251 million studies, and linkage to ~47 million tokenized patients via Datavant. Two new customers have contracted for the platform as the company pursues subscription-based annual recurring revenue.
OneMedNet (Nasdaq: ONMD) reported strong 2025 results driven by its AI‑driven iRWD™ platform powered by Palantir Foundry. Key 2025 metrics include RWD revenue up 329% YoY to $1.254M, Q4 revenue above $890,000, and total liabilities cut 74% to $5.1M.
The company reduced its shareholder deficit to $(3.0M), has 2 pilot customers in contracting, expects 4 additional seven‑figure subscription customers in H2 2026, and projects 4x platform growth by end of 2026.
OneMedNet (Nasdaq: ONMD) announced a collaboration with Onco-Innovations and its subsidiary Inka Health to provide access to OneMedNet’s iRWD™ platform, powered by Palantir Foundry, for U.S. oncology real-world data. The pilot focuses on accelerating development and evidence generation for Onco’s PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.
The agreement will support patient responder identification, indication expansion beyond metastatic colorectal cancer, and SynoGraph™ model development.
OneMedNet (Nasdaq: ONMD) announced a strategic collaboration with Navidence on March 18, 2026 to integrate Navidence Computable Operational Definitions (CODefs) into the OneMedNet iRWD™ platform.
This integration aims to accelerate cohort discovery, improve dataset fitness, and support regulatory‑grade real‑world evidence for pharma and CRO customers.
OneMedNet (Nasdaq: ONMD) announced the next phase of its commercial launch for a Palantir Foundry–powered Real‑World Data (RWD) platform on February 27, 2026. The company is converting evaluations into multi‑year subscriptions said to represent millions in incremental ARR and scaling an iRWD network spanning 2,130+ healthcare sites.
The platform claims continuous live feeds, 20+ years of historical depth, three years forward coverage, AI‑driven search, faster cohort feasibility, and broader multimodal data to support RWE generation and recurring, high‑margin revenue growth.
OneMedNet (NASDAQ: ONMD) announced a strategic partnership with ViuHealth to add ongoing, longitudinal autoimmune disease data to the OneMedNet iRWD™ platform, powered by Palantir Foundry. The deal aims to expand dataset scale, diversity, and depth to support drug development, AI model training, HEOR, and subscription revenue growth.
The addition emphasizes recurring-license demand by enriching disease-specific cohorts and cites autoimmune therapeutics markets projected above $166 billion and ~8% U.S. prevalence as key market drivers.
OneMedNet (Nasdaq: ONMD) announced a strategic data licensing agreement with Risorius to supply large-scale EEG and PSG waveform data paired with longitudinal clinical context. Data delivery is underway via a three-month project under a multi-year subscription licensing model, intended to support Risorius’ EEG-based digital biomarker R&D and AI platform validation.
The deal reportedly adds multi-year subscription contracts representing millions of dollars in incremental recurring revenue and was executed in record time, highlighting OneMedNet’s commercial momentum in the neuro/CNS vertical.
OneMedNet (Nasdaq:ONMD) reported record 2025 bookings of $2.79 million, a 4.1X increase versus 2024, driven by larger enterprise deals and a shift toward recurring subscriptions. The company highlighted Palantir-powered Subscription Search and Subscription Data License products as core drivers of higher ARR and deal sizes.
Management said subscription agreements signed in 2Q and 3Q 2025 with named customers underpin a pipeline entering 2026 focused on near-real-time multimodal RWD and higher-margin recurring revenue.
OneMedNet (Nasdaq: ONMD) announced that its regulatory-grade Real-World Data supported mlHealth 360 in obtaining FDA 510(k) clearance for Scaida BrainCT-ICH, an AI software to detect intracranial hemorrhage from head CT scans. OneMedNet supplied multimodal datasets spanning longitudinal EMR, diagnostic imaging, and clinical reports to support model development, validation, and the regulatory submission. Scaida BrainCT-ICH identifies suspected ICH in approximately 5.97 seconds after image acquisition, which the companies say enables faster clinical triage.
This milestone is presented as validation of OneMedNet’s data quality and its role as a trusted partner for regulated AI and life‑sciences submissions.
OneMedNet (Nasdaq: ONMD) delivered an anonymized Real-World Data feed covering 1.5 million patients and 4 million encounters to a healthcare data and analytics organization on January 2026. The multimodal dataset exceeds 1.49 billion datapoints and includes longitudinal clinical domains such as practitioner notes, immunizations, conditions, medications, encounters, and observations. Delivered under OneMedNet’s subscription model and powered by Palantir AIP Foundry, the feed supported enterprise-scale testing, validation, and demonstrated ingestion, harmonization, and operationalization of complex healthcare data, positioning the company to scale subscription-based RWD delivery and pursue additional customers.